logo

Omeros Corp. (OMER)



Trade OMER now with
  Date
  Headline
6/14/2021 8:40:39 AM Omeros Presents Data On Organ Function Improvement From Its Pivotal Trial Of Narsoplimab
6/10/2021 8:48:06 AM Omeros Publishes Detailing Mechanism Of Action Of PDE7 In Nicotine Addiction
6/9/2021 8:55:12 AM Omeros Announces Preliminary Results From Phase 1 Trial Of OMS906 In PK, PD; OMS906 Well Tolerated At All Doses Tested
5/13/2021 8:33:35 AM Omeros' Narsoplimab Pivotal Trial Data To Be Shared As Oral Presentation At European Hematology Association Congress
5/4/2021 6:30:26 AM Omeros Corp: CDC Approves ICD-10 Diagnosis Code For HSCT-TMA Diagnosis And For Narsoplimab Administration
3/23/2021 8:50:56 AM Omeros And Quantum Leap Dose First Patients With Narsoplimab In I-SPY COVID-19 Trial
7/15/2019 6:17:18 AM Wedbush Reiterates Omeros Corp. (OMER) At Neutral With $18 Price Target
5/20/2019 10:05:44 AM Wedbush Is Lowering Omeros Corp. (OMER) FY19 Rev. Estimate To 96.7 M From 97.2 M
5/20/2019 10:05:20 AM Wedbush Is Cutting Omeros Corp. (OMER) FY20 Estimate To -2.13 From -0.96
5/20/2019 10:05:06 AM Wedbush Is Lowering Omeros Corp. (OMER) Q4 20 Estimate To -0.83 From -0.52
5/20/2019 10:04:51 AM Wedbush Is Cutting Omeros Corp. (OMER) Q3 20 Estimate To -0.44 From -0.14
5/20/2019 10:04:40 AM Wedbush Is Cutting Omeros Corp. (OMER) Q2 20 Estimate To -0.43 From -0.15
5/20/2019 10:04:29 AM Wedbush Is Lowering Omeros Corp. (OMER) Q1 20 Estimate To -0.43 From -0.16